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Abstract. Researches of the last years showed that changes of local immunity at inflammatory 
diseases of appendages at women, to be exact a condition of a secondary immunodeficiency at the 
local level, arising against the main pathological process, are a consequence of an immune 
inflammation, violation of structure and function of cellular membranes because of lipid 
peroxidation. Research objective was establishment of changes of the metabolic status at an 
aggravation chronic salpingoophoritis and detection of efficiency of use in «Gepon's» complex 
pharmacotherapy and «Longidaza's» various medicinal forms. For this purpose under continuous 
supervision was the 70th women aged from 20 till 35 years with the established diagnosis chronic 
salpingoophoritis in an aggravation stage. All patients were divided into four groups according to 
age, minimum satellite, severity of illness and providing treatment. The first experimental group 
was included 18 patients with chronic adnexitis in the exacerbation phase, where the standard 
therapy. The second group was included patients (17 women), which put on «Longidaza» in the 
form of suppositories (1 suppository 3000 per recti 1 times a day for 5 days). In the third group 
(18 patients), patients received, in addition to a standard treatment regimen «Gepon» (10 mg per 1 
times a day for 5 days). The fourth group was included patients (17 women), which put on 
«Longidaza» injections (1 suppository 3000 intramuscularly 1 time per day for 5 days). As a 
result of a research efficiency of use of immunocorrective preparations («Gepon» and 
«Longidaza») at patients chronic salpingoofority in an aggravation stage in correction of 
metabolic frustration is established. «Longidaza's» use in the form of candles has corrective and 
normalizing impact on the broken indicators of the metabolic status at patients chronic 
salpingoophoritis at local level whereas purpose of an injection form of this preparation 
normalizes parameters of the oxidatic status at system level. Results of a research allow to draw a 
conclusion that application in complex pharmacotherapy of patients with chronic 
salpingoophoritis longidaza and gepon in comparison with standard treatment makes more 
expressed impact on clinical picture of disease and laboratory indicators at system and local 
levels, thus maximum efficiency possesses a preparation of longidaza in the form of injections. 
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Introduction. In modern tearms of chronical 
inflammatory conditions, of the uterine appendages, 
are the actual problem of obstetrics and gynecology 
due to unexpressed clinical aspects. Extent of 
exposure, frequent relapses, leading to the 
development of adhesive processes, in the small 
pelvis, a breach of immunological reactivity and 
other changes [1, 2, 3, 4]. The systemic protection 
mechanisms , are diseases in cases of long-stretching 
and recurrent diseases of the uterine appendages 
against which it is most likely a violation of the 
pelvic organs with the development of the power of 
local tissue hypoxia [5, 6, 7]. There is a study about 
production, of inflammatory mediators of different 
nature a relatively new subject of study pathogenetic 
mechanisms of inflammation in the uterine 
appendages of women antioxidant protection, from 
which expression depends on changes in the level 
body, systems and organism as a whole [8, 9]. 
Recent researches have shown, changes in local 
immunity the state of the secondary 
immunodeficiency at the local level that occurs on a 
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background of the primary pathological process, are 
the result of immune inflammation, disruption of the 
structure and function of cell membranes due to lipid 
peroxidation [10]. 
The use of anti-inflammatory medication 
therapy has an active effect on the bacterial flora, but 
not enough to impair immune and metabolic status, 
which is opened the prospect of doing research to 
find effective ways and means of pharmacological 
immunoreabilitation [11]. 
Accordingly, only the use of standard therapy, 
doesn’t always lead to full recovery. So for the 
successful treatment of patients, with chronic 
inflammatory diseases,it must be integrated 
etiopathogenetic treatment, including an appropriate 
immune rehabilitation and prevention of adhesions 
[12]. 
As the results of previous researches using only 
immunomodulatory drugs in the correction of 
immune and oxidant disturbances that occur during 
exacerbation of chronic adnexitis is not enough, so in 
this respect it could be effective to use the drug with 
immunomodulating and enzymatic activity. 
Longidaza, being a derivative polyoxidonium in 
conjunction with hyaluronidase, and in a variety of 
pharmaceutical forms of its release [13, 14]. There 
are enough facts for appropriate effectiveness of the 
injection Longidaza, while suppository form of the 
drug has been understudied [15]. Also, it may be a 
promising application Gepon drug interferon inducer 
link immunity [16, 17]. 
On this basis, the development of 
pathogenetically substantiated pharmacotherapeutic 
strategy exacerbation of chronic adnexitis is one of 
the urgent problems of modern medicine. 
Our objective: To identify the clinical and 
immunological effectiveness using complex 
processes, in the pharmacotherapy of acute 
exacerbations of chronic adnexitis Gepon and 
different dosage forms Longidaza. 
Research objectives: 
– To determine effects of Gepon on the immune 
status and lipid peroxidation in patients with chronic 
adnexitis in the exacerbation phase. 
– To determine the effect of various dosage 
forms of pharmacotherapy, drug «Longidaza» on the 
immune status, and processes peroxidation, lipid in 
patients with chronic adnexitis in the exacerbation 
phase. 
– To compare immunomodulatory and 
antioxidant effects «Gepon» and «Lonegidaza» in the 
form of suppositories or injectable solution in 
complex patients with acute exacerbation of chronic 
adnexitis. 
– To compare the clinical and immunological 
effectiveness of methods, pharmacorrection including 
immunotropic drugs in patients suffering from 
chronic adnexitis in the exacerbation phase. 
– To identify correlations between clinical 
symptoms, and laboratory parameters for inclusion in 
a comprehensive standard pharmacotherapy, Gepon 
and Longidaza and an exacerbation of chronic 
adnexitis. 
It was established clinical and immunological 
efficacy immunocorrective drugs («Gepon» and 
various forms of «Lonegidaza») in patients, with 
chronic adnexitis in the exacerbation phase. Using 
«Longidaza» in the form of suppository has a 
corrective and normalizing effect on the impaired 
performance immune status of patients with chronic 
adnexitis mostly at the local level, while the 
appointment of the injectable form of the drug 
normalizes immune parameters and oxidative status 
at the system level. The use of complex 
pharmacotherapy of patients with chronic adnexitis 
«Longidaza» and «Gepon» is compared with 
standard treatment and had more pronounced effect 
on the clinical symptoms disease and laboratory 
parameters on the system and local levels, with the 
maximum efficiency has drug injection «Longidaza». 
There were effective complex methods for 
patients with chronic pharmacotherapy adnexitis in 
the exacerbation phase using «Gepon» or 
«Longidaza». Clinical and immunological efficacy of 
the applied sketch of pharmacotherapy of patients 
with chronic adnexitis is ascending in the following 
order: standard pharmacotherapy  standard therapy 
+ «Gepon» standard therapy + «Longidaza» in the 
form of suppositories  standard therapy treatment + 
«Longidaza» in the form of injections. 
There were significant interactions between 
indicators immunnometabolic status on the system 
and local levels, and clinical symptoms that gives an 
indication of the effectiveness of the treatment, the 
dynamics of symptom exacerbation of chronic 
adnexitis and predicting disease outcome. 
In clinical research it was used a team approach 
to the study of immunocorrective and antioxidant 
effects of immunomodulatory drugs in women of 
gynecological separation OBUZ «Regional Perinatal 
Center» in Kursk with chronic adnexitis in the 
exacerbation phase, in accordance with the 
recommendations of the World Health Organizations. 
The learning of pharmacological corrective 
effects «Gepon» (LLC «Immapharma», Russia) and 
«Longidaza» («research and manufacturing 
association Petrovax Farm», Russia) on the immune, 
oxidative disorders and clinical symptoms in patients 
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with chronic adnexitis in the exacerbation phase was 
carried out using an enzyme multiplied 
immunoassay, laboratory methods for assessing 
oxidative indicators, activity of antioxidant systems 
and using widely certified methods of statistical data 
processing. 
OWN RESEARCHES 
Clinical impressions. There were 70 patients 
with chronic adnexitis in the exacerbation phase at 
the age of 20-35 years under constant surveillance on 
the basis of OBUZ «Regional Perinatal Center». 
Clinical exclusion was established on the basis of 
complaints, medical history, laboratory and physical 
examination [18, 19]. The control group consisted of 
22 healthy volunteer donors of the same age. The 
inclusion criteria were: 
– The age of 20-35 years; 
– Medical history to 3 years; 
– Сertain disease is chronic adnexitis in the 
exacerbation phase; 
– The severity of the state no more than 
moderate severity; 
– Negative findings of STD; 
– Tolerance of used drug ; 
– A written consent to participate in doing 
research. 
Exclusion criteria: 
– Patients in serious and critical condition; 
– Verified persons with specific STD; 
– Persons with concomitant somatic pathology 
in the stage of incomplete remission and the 
exacerbation phase; 
– Persons with an allergic reaction to the 
treatment; 
– Patients who refuse to doing research. 
In all cases, it was carried out direct microscopic 
for the exclusion of gonococcus infection (swabs 
were prepared then they were stained with 1% 
aqueous methylene blue and Gram) and biological 
(inoculation of medium for detecting Neisseria 
gonorrhea) research of vaginal-cervical lavage. 
To detect trichomonas it was carried out native 
and painted watercolor solution of methylene blue 
drugs, inoculation of medium for the culture 
diagnosis of trichomoniasis. 
Diagnosis of chlamydia, mycoplasma, 
ureaplasma, gardnerela infection was producing by 
examining scraps obtained PCR using commercial 
kits firm «DNA diagnosis» All patients were 
subjected to testing for lues and HIV, which staged 
the standard serological tests. All patients made 
direct microscopic and bacteriological content of the 
Exploration of the cervical canal and urethra, 
performed a colposcopy, ultrasound investigation. 
Laboratory methods of blood tests were carried 
out by conventional methods. It were taken 
hemogram as a basis for the physiological norm, 
corresponding to the international system of units 
(SI) in clinical trials. 
All patients were divided into four groups 
according to age, minimum satellite, severity of 
illness and providing treatment (Table 1). 
The first experimental group was included 18 
patients with chronic adnexitis in the exacerbation 
phase, where the standard therapy is held: cefazolin 
(1.0 intramuscularly 4 times a day number 20), 
gentamicin (80 mg intramuscularly 3 times a day 
number 21), nystatin (500 thousand units inside. 4 
times a day № 28) trichopolum (0,5 orally 3 times 
daily № 15) indometacinum (100 mg once per rectum 
№ 10) and clotrimazole topically (Table 1. per vagina 
singly evening № 10). 
Table 1. 
Distribution of patients according to the method of treatment. 
Patients with chronic 
adnexitis in the 
exacerbation phase 
№ Treatment mode Number 
1 Standard medicinal treatment 18 
2 Standard medicinal treatment + «Longidaza» suppositories 17 
3 Standard medicinal treatment + «Gepon» 18 




The second group was included patients (17 
women), which put on «Longidaza» in the form of 
suppositories (1 suppository 3000 per recti 1 times a 
day for 5 days). 
In the third group (18 patients), patients 
received, in addition to a standard treatment regimen 
«Gepon» (10 mg per 1 times a day for 5 days). 
The fourth group was included patients (17 
women), which put on «Longidaza» injections  
(1 suppository 3000 intramuscularly 1 time per day 
for 5 days). 
All drugs were administered according to the 
guidelines outlined in the guide «Medicines», 
«Doctor-register own funds of Russia» (2010) and 
instructions on the use of drugs. 
Laboratory research. Content FNOα, IL-18, 
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INFα, IL-10, C3 and C4 components of the 
complement system, factor H was determined in the 
blood plasma and cervical-vaginal lavage with the 
help of ProCon reagent kit (LLC «Protein contour», 
St. Petersburg) by enzyme immunoferment analysis. 
Intensity of lipid peroxidation was evaluated on 
the content in the blood and cervical-vaginal lavage 
malonic dial [20]. The measured activity of catalase 
[21], SOD, the concentration of ceruloplasmin-
governmental stable metabolites of nitric oxide [22], 
α1-antitrypsin, α2-macroglobulin and total antioxidant 
activity of blood serum [23]. 
Erythrocytes were prepared from 5 ml 
heparinized blood by the method of E. Beutler with 
minor modification. Whole blood is asserted twice in 
10 mM Na-phosphate buffer (pH 7.4) containing 
0.9% sodium chloride and 3% dextran T-500, for 30 
minutes at 37 ° C. Thereafter, the blood was 
centrifuged, the supernatant was removed by 
aspiration. Packed red blood cells were further 
purified to the chromatographic column through 
HBs-cellulose. 
We determined the total sorption capacity of red 
blood cells and the sorption capacity of glycocalyx. 
On the functional state of erythrocytes as judged 
by the accumulation of malonic dial and activity of 
superoxide dismutase. 
Statistical analysis of the results. Statistical 
processing of results of research was carried out 
using non-parametric methods, factor analysis, 
cluster analysis, and Spearman's rank correlation 
coefficient. Differences were considered statistically 
significant with p <0,05. 
For immunological parameters were calculated 
ratio diagnostic value, determined by the formula of 
immune disorders system by selecting from all the 
studied parameters of the top three most 
distinguished level of standards expected level of 
immune disorders, ranking algorithm largest extent 
disorders conducted. 
Correlation analysis between indices 
immunometabolic and clinical data, calculated the 
amount of degrees of correction for each treatment 
regimen. 
RESULTS OF RESEARCH 
Immune and metabolic disorders in patients 
with chronic adnexitis in the exacerbation phase 
before and after standard treatment. The studied 
parameters of patients with chronic adnexitis in the 
exacerbation phase in the surveyed group to the 
treatment of each other do not differ. Patients with 
chronic adnexitis in the exacerbation phase plasma at 
admission to hospital revealed increasing 
concentrations FNOα, IL-18, INFα, C3 and C4 
components of the complement system and reduced 
levels of IL-10 over 4 pain and factor H (Table 2). 
Using the standard treatment in patients with 
chronic adnexitis in the exacerbation phase allowed 
to reduce, but not to the level of standards, the 
concentration of IL-18, C3 and C4 of the complement 
system and the Component to increase the 
concentration of factor H (Table 2). 
 
Table 2. 
Cytokines and complement concentration of system components in patients with chronic adnexitis  
in the exacerbation phase plasma on a background of standard treatment. 
Exponents Units 
1 2 3 
Healthy 
Patients with chronic adnexitis in the 
exacerbation phase 
Before treatment After treatment 
FNОα pg/ml 1,77±0,08 5,8±0,15*1 5,48±0,25*1 
IL-18 pg/ml 40,45±2,35 195,8±8,8*1 150,1±10,35*1,2 
IL-10 pg/ml 18,5±0,42 3,5±0,2*1 3,89±0,24*1 
INFα pg/ml 11,5±1,21 28,6±3,4*1 26,2±2,19*1 
С3 pg/ml 106,4±6,9 228,2±7,6
*1
 152,48±7,17*1,2 
С4 mg/dl 13,6±1,31 47,7±1,6
*1
 40,01±1,24*1,2 
Factor Н ng/ml 41,3±3,3 23,7±2,9*1 34,8±3,17*1,2 
Note. Hereafter the asterisk marked significant differences of average arithmetical (p <0,05); figures close to the star are in 
relation to that of a group of these differences. 
 
In the cervical-vaginal lavage in women with 
chronic adnexitis in the exacerbation phase revealed 
raising FNOα, IL-18, INFα, system components 
plementa someone, but the decline in the level of 
secretory IgA, factor H and IL-10 (Table 3). Against 
the background of standard treatment in patients with 
chronic adnexitis in the exacerbation phase in the 
vaginal-cervical lavage is reduced, but not to the 
level of standards, the concentration of IL-18, INFα 
and increased levels of IL-10 (Table 3). 
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Table 3. 
The concentration of cytokines and complement components in patients current with chronic adnexitis  
in the exacerbation phase in the vaginal-cervical lavage against standard treatment (M ± m). 
 
Exponents Units 
1 2 3 
healthy 
Patients with chronic adnexitis in the exacerbation phase 
Before treatment After treatment 
FNОα pg/ml 1,19±0,08 6,1±0,2*1 6,65±0,46*1 
IL-18 pg/ml 2,58±0,13 14,3±0,9*1 10,91±0,89*1,2 
IL-10 pg/ml 5,12±0,77 1,8±0,14*1 3,94±0,57*1,2 
INFα pg/ml 8,37±0,59 14,5±1,1*1 10,8±1,2*1,2 
С3 mg/dl 24,3±2,9 40,6±1,7
*1
 41,55±2,08*1 
С4 mg/dl 1,13±0,07 2,5±0,02
*1
 2,42±0,11*1 
Factor Н ng/ml 29,8±2,14 17,3±1,1*1 18,0±1,21*1 
sIgA mg/dl 37,6±1,24 31,8±0,1*1 31,96±1,09*1 
 
In the blood plasma of patients with identified 
chronic adnexitis in the exacerbation phase raising 
MDA, α1-AT, α2-MG, stable metabolite of nitric 
oxide in reducing CRP during General antioxadantive 
activity serum, SOD and catalase activity, the 
concentration of ceruloplasmin (Table 4). 
On the background of the standard treatment for 
this category of patient current plasma malonic dial 
concentration decreases, CRP, proteolytic ferments, 
but increased the activity of catalase, SOD, General 
antioxadantive activity , but not to the level healthy  
donors (Table 4). 
Table 4. 
Indicators of metabolic status of patients with chronic adnexitis in the exacerbation phase in the blood on the 
background of standard treatment (M ± m). 
 
Exponents Units 
1 2 3 
healthy 
patients with chronic adnexitis in the exacerbation phase 
Before treatment After treatment 
Malonic dial umol/l 1,98±0,15 4,1±0,08*1 3,8±0,05*1,2 
General antioxadantive 
activity 
% 50,1±0,99 39,3±0,7*1 43,2±0,56*1,2 
SOD  U/ml 12,8±0,99 4,2±0,2*1 5,93±0,34*1,2 
Catalase µkat/L 22,65±1,63 11,4±0,3*1 12,86±0,28*1,2 
ceruloplasmin mg/dl 33,2±2,05 24,5±1,9*1 22,0±1,19*1 
СМNO umol/l 3,68±0,21 4,0±0,1
*1
 2,82±0,09*1,2 
α1-AT mg/dl 80,6±4,3 134,3±3,7
*1
 90,88±2,3*1,2 
  α2-MG mg/dl 89,57±2,09 140,4±6,1
*1
 113,0±3,48*1,2 
CRP mg/dl 1,35±0,33 2,1±0,04*1 1,73±0,08*1,2 
 
In the cervical-vaginal lavage women with 
chronic adnexitis in the exacerbation phase revealed 
increased concentration of malonic dial, stable 
metabolites of azote oxide, α1-AT, α2-MG and 
reducing General antioxadantive activity, the activity 
of SOD, catalase, the concentration of ceruloplasmin 
(Table 5). 
Table 5. 
Indicators of metabolic status of patients with chronic adnexitis in the exacerbation phase in the vaginal-cervical lavage 
on a background of standard treatment (M ± m). 
Exponents Units 
1 2 3 
healthy 
patients with chronic adnexitis in the exacerbation 
phase 
Before treatment After treatment 
Malonic dial umol/l 0,87±0,03 2,1±0,05*1 1,98±0,08*1 
General antioxadantive 
activity 
% 15,6±1,12 4,8±0,27*1 7,46±0,45*1,2 
SOD U/ml 2,07±0,08 0,5±0,05*1 0,62±0,09*1 
Catalase µkat/L 3,16±0,09 1,5±0,18*1 1,14±0,34*1 
ceruloplasmin mg/dl 2,48±0,04 0,7±0,06*1 0,97±0,04*1,2 
СМNO umol/l 0,51±0,03 0,6±0,05
*1
 0,46±0,04*2 
α1-АТ mg/dl 13,7±0,71 40,0±2,06
*1
 15,7±0,98*2 




 Abramova S.N., Lazareva G.A. Pharmacotherapy exacerbations of chronic inflammatory conditions 
of female genital sphere using to Gepon and Longidaza. Research result: pharmacology  
and clinical pharmacology. Vol. 2, №4 (2016): 55-67. 
60 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
Using a standard treatment regimen in patients 
with chronic adnexitis in the exacerbation phase 
possible to normalize the level of α1-AT, but to 
correct burdened obstetric history, concentration of 
ceruloplasmin, without affecting the rest of the 
indicators changed in the metabolic status (Table 5). 
We have further studied the sorption properties 
of red blood cells and the concentration within them 
of malonic dial and SOD activity. Thus, in patients 
with chronic adnexitis in the exacerbation phase in 
erythrocyte malonic dial concentration increased and 
reduced on-SOD activity (Figure 1). 
 
Figure 1. The state of immune and metabolic status in patients with chronic adnexitis in the exacerbation phase at the local level. 
 
In addition, when you receive in this category of 
patients increased sorption properties of erythrocytes: 
sorption capacity of erythrocyte and sorptive capacity 
glycocalyx (Figure 1.). Against the background of 
standard treatment in patients with chronic adnexitis 
in the exacerbation phase concentration decreases in 
erythrocyte malonicdial, but not to the level of 
standards, while other indicators remain at the same 
level changed (Figure 1). 
Comparing the total number of different 
parameters of normal levels in patients with chronic 
adnexitis in the exacerbation phase found that if such 
indicators before treatment was 96.6%, after the 
standard pharmacotherapy such indicators was 94.2, 
which is not enough (table 6).  
Table 6. 
The effectiveness of standard treatment in patients with chronic adnexitis in the exacerbation phase (% Indicators). 
 
Indicators 
(% Of the total number of indicators) 
Standard treatment 
Excellent level of standards before treatment 96,6 
normilized 2,4 
corrected 23,3 
Not changing 70,9 
Excellent level of standards after standard therapy 94,2 
 
Immune efficacy of «Gepon» and 
«Longidaza» in patients with chronic adnexitis in 
the exacerbation phase. Using «Longidaza» in the 
form of suppositories for patients with chronic 
adnexitis in the exacerbation phase in addition to a 
standard treatment regimen will normalize the blood 
concentration of the C3 component of complement 
system, INFα, reduce, but not to the level of 
standards, the level FNOα, IL-18, C4 component of 
the complement system (Table 7). 
At the local level in patients with chronic 
adnexitis in the exacerbation phase against 
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application «Longidaza» in the form of suppositories 
to normal levels of IL-18, INFα, C4 component of 
the complement system, of sIgA, corrected, but not to 
the level of standards, the concentration of FNOα, 
factor H (Table 8). 
Appointment «Longidaza» in the form of 
suppositories patients with chronic adnexitis in the 
exacerbation phase additory to the standard treatment 
regimen helped normalize blood concentration of 
ceruloplasmin, CRP increase, but not to the level of 
standards, SOD activity, catalase, α2-MG (Table 7). 
Women with chronic adnexitis in the 
exacerbation phase against application «Longidaza» 
in the form of suppositories in the vaginal-cervical 
lavage normalized level of malonic dial, SMNO 
proteolysilytic enzymes, corrected, but not to the 
level of standards activity catalase, SOD and the level 
of ceruloplasmin (Table 8). 
Using «Gepon» in patients with chronic 
adnexitis in the exacerbation phase in addition to the 
standard treatment regimen helped correct the 
concentration in the blood FNOα, IL-18, INFα, but 
further increases the concentration of component B 
tem Complement: C3 and complement C4 
component (Table 7). 
At the local level in patients with chronic 
adnexitis in the exacerbation phase against 
application «Gepon» only corrected concentration of 
IL-18, and other indicators of immune status remain 
at the same level changed (Table 8). 
Appointment «Gepon» patients with chronic 
adnexitis in the exacerbation phase, in addition to the 
standard treatment regimen has allowed to correct 
blood SOD and catalase, the concentration of 
ceruloplasmin (Table 7). 
Women with chronic adnexitis in the 
exacerbation phase against application «Gepona» in 
the vaginal-cervical lavage normalized level α1-AT, 
corrects the activity of catalase (Table 8). 
Using «Longidaza» in the form of injections in 
patients with chronic adnexitis in the exacerbation 
phase additionally to the standard treatment regimen 
helped normalize blood concentration FNOα, C3 and 
C4 component of the complement system, INFα, the 
fact that H, corrected, but not to the level of 
standards, IL level -18 and IL-10 (Table 7). 
At the local level in patients with chronic 
adnexitis in the exacerbation phase against 
application «Longidaza» in the form of injections 
corrected FNOα level and IL-18 (Table 8). 
Appointment «Longidaza» in the form of 
injections patients with additional chronic adnexitis 
in the exacerbation phase  to the standard treatment 
regimen helped normalize blood concentration of 
ceruloplasmin, α1-AT, CRP increase, but not to the 
level of standards of asset are SOD and catalase, the 
concentration of α2- MG (Table 7). Women with 
chronic adnexitis in the exacerbation phase  against 
application «Longidaza» in the form of injections in 
the vaginal-cervical lavage normalized level of 
malonic dial, General antioxadantive activity, SMNO 
and α2-MG, corrected, but not to the level of 
standards, catalase activity and the level of α1-AT 
(Table 8). The use of «Gepon» corrects inside the 
erythrocytes malonic dial level and sorption capacity 
of erythrocyte, «Longidaza» in the form of 
suppositories  further sorptive capacity glycocalyx, 
while the use of «Longidaza» in the form of 
injections normalize sorption properties of red blood 
cells (Figure 2). 
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Table 7. 
Immune and metabolic status at the system level in patients with chronic adnexitis in the exacerbation phase the therapy (M ± m). 
Exponents Units 
1 2 3 4 5 6 7 
healthy 
patients with chronic adnexitis in the exacerbation phase 
Standard treatment 




+ «Longidaza» injections 
Before treatment After treatment 
Before 
treatment 
After treatment Before treatment After treatment 
FNОα pg/ml 1,77±0,08 6,0±0,15*1 2,51±0,06*1,2 5,9±0,15*1 3,59±0,15*1,4 5,8±0,15*1 1,79±0,07*6 
IL-18 pg/ml 40,45±2,35 198,4±9,8*1 137,73±4,33*1,2 190,7±8,7*1 70,17±2,58*1,4 191,7±10,2*1 53,1±2,4*1,6 
IL-10 pg/ml 18,5±0,42 3,7±0,2*1 3,35±0,15*1 3,6±0,3*1 3,64±0,11*1 3,3±0,2*1 9,8±1,09*1,6 
INFα pg/ml 11,5±1,21 27,5±2,5 *1 12,5±1,96*2 28,8±3,1*1 20,4±2,3*1,4 29,9±3,1*1 12,03±2,14*6 
С3 mg/dl 106,4±6,9 246,1±12,1
*1
 112,9±3,2*2 212,8±9,6*1 175,64±4,04*1,4 230,8±10,5*1 115,47±2,18*6 
С4 mg/dl 13,6±1,31 49,1±1,8
*1
 25,92±0,88*1,2 43,5±1,7*1 56,06±1,7*1,4 50,6±1,3*1 14,83±1,45*6 
Factor Н ng/ml 41,3±3,3 25,1±1,8*1 32,8±4,7*1,2 24,2±1,4*1 30,2±2,51*1,4 23,2±1,9*1 43,5±4,0*6 
MDA umol/l 1,98±0,15 1,98±0,15 4,3±0,09*1 4,0±0,07*1 3,62±0,16*1,4 4,4±0,09*1 2,43±0,07*1,6 
ОАА % 50,1±0,99 50,1±0,99 39,5±0,8*1 38,8±0,8*1 42,59±0,66*1,4 40,1±0,8*1 44,45±0,69*1,6 
SOD U./ml 12,8±0,99 12,8±0,99 4,5±0,3*1 4,1±0,3*1 9,06±0,89*1,4 4,1±0,3*1 8,13±0,24*1,6 
Catalase µkat/L 22,65±1,63 22,65±1,63 11,1±0,4*1 10,9±0,3*1 14,23±0,17*1,4 11,3±0,3*1 18,46±0,19*1,6 
ceruloplasmin mg/dl 33,2±2,05 33,2±2,05 24,8±1,8*1 23,8±1,8*1 25,36±1,29*1 22,8±1,9*1 31,06±3,5*6 
СМNO umol/l 3,68±0,21 3,68±0,21 4,2±0,7
*1
 4,1±0,2*1 2,6±0,16*1,4 4,2±0,2*1 2,82±0,11*1,6 
α1-AT mg/dl 80,6±4,3 80,6±4,3 141,2±3,8
*1
 131,8±3,8*1 91,2±2,5*1,4 131,4±3,6*1 81,3±1,87*6 
  α2-MG mg/dl 89,57±2,09 89,57±2,09 141,8±6,2
*1
 135,9±6,1*1 136,8±3,66*1 134,6±6,2*1 96,4±2,56*1,6 
CRB mg/dl 1,35±0,33 1,35±0,33 2,2±0,05*1 2,3±0,08*1 1,91±0,09*1 2,0±0,04*1 1,52±0,03*6 
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Table 8. 
Immune and metabolic status at the local level in patients with chronic adnexitis in the exacerbation phase the therapy (M ± m). 
 Units 
1 2 3 4 5 6 7 
healthy 
patients with chronic adnexitis in the exacerbation phase 
Standard treatment 




+ «Longidaza» injections 
Before treatment After treatment 
Before 
treatment 
After treatment Before treatment After treatment 
FNОα pg/ml 1,19±0,08 6,5±0,3*1 2,52±0,39*1,2 6,3±0,2*1 6,19±0,26*1 5,9±0,3*1 4,75±0,36*1,6 
IL-18 pg/ml 2,58±0,13 12,8±0,8*1 2,69±0,33*2 14,5±0,9*1 6,2±0,7*1,4 15,6±0,7*1 6,95±0,49*1,6 
IL-10 pg/ml 5,12±0,77 1,9±0,1*1 3,39±0,22*1,2 1,7±0,1*1 3,42±0,06*1,4 1,7±0,15*1 3,04±0,22*1,6 
IНФα pg/ml 8,37±0,59 12,9±1,2*1 9,07±1,05*2 14,9±0,9*1 11,3±2,4*1,4 15,3±1,0*1 10,12±1,05*1,6 
С3 mg/dl 24,3±2,9 36,6±1,9
*1
 40,68±3,76*1 46,7±1,6*1 40,67±2,2*1 40,2±1,1*1 40,31±4,05*1 
С4 mg/dl 1,13±0,07 2,2±0,03
*1
 1,45±0,32*2 2,6±0,02*1 2,51±0,47*1 2,9±0,02*1 2,27±0,09*1 
Factor Н ng/ml 29,8±2,14 16,1±1,0*1 23,8±1,27*1,2 17,8±1,1*1 16,9±2,05*1 18,1±1,2*1 18,4±2,3*1 
sIgA mg/dl 37,6±1,24 30,2±0,4*1 38,76±3,02*2 37,9±0,1*1 31,64±2,2*1 33,8±0,3*1 30,5±1,78*1 
MDA umol/l 0,87±0,03 2,3±0,06*1 0,91±0,03*2 2,2±0,06*1 2,05±0,05*1 2,0±0,06*1 1,38±0,04*6 
ОАА % 15,6±1,12 4,4±0,3*1 13,3±0,49*1,2 4,9±0,25*1 7,82±0,54*1,4 4,6±0,3*1 14,76±0,56*6 
SOD U./ml 2,07±0,08 0,6±0,05*1 1,73±0,07*1,2 0,4±0,04*1 0,72±0,02*1,4 0,6±0,06*1 0,63±0,03*1,6 
Catalase µkat/L 3,16±0,09 1,4±0,1*1 2,86±0,12*1,2 1,6±0,15*1 2,05±0,11*1,4 1,4±0,09*1 2,01±0,13*1,6 
ceruloplasmin  mg/dl 2,48±0,04 0,8±0,07*1 2,1±0,04*1,2 0,6±0,07*1 0,94±0,02*1,4 0,8±0,07*1 0,9±0,04*1,6 
СМNO umol/l 0,51±0,03 0,6±0,08
*1
 0,45±0,04*2 0,7±0,06*1 0,44±0,05*4 0,6±0,06*1 0,47±0,03*6 
α1-АT mg/dl 13,7±0,71 38,6±2,2
*1
 12,97±0,63*2 40,2±2,05*1 13,37±0,56*4 42,1±2,1*1 19,53±7,36*1,6 
  α2-MG mg/dl 18,09±1,13 26,2±2,2
*1
 17,72±1,36*2 24,1±2,1*1 24,9±2,07*1 27,1±2,1*1 18,4±0,46*6 
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Comparative clinical and laboratory 
efficiency «Gepon» and another forms 
«Longidaza» in patients with chronic adnexitis. 
Using «Gepon» normalizes 16.6% of the indicators, 
and the use of «Lonegidaza» in the form of 
suppositories - 28.6%, which reduced the number of 
indicators other than the level of the norm to 77.6 and 
65.6%. At the same time the using of «Longidaza» in 
the form of  injections in patients with chronic 
adnexitis in the exacerbation phase allowed 
normalized larger number of indicators, making 
lower the number of modify to 58.8% (Table 9). 
Table 9. 
Efficiency of pharmacological diagram in patients with chronic adnexitis in the exacerbation phase (% indicators). 
exponents 
(% from the total exponents) 
Standard therapy + 
«Gepon» 
Standard therapy + 
«Longidaza» 
suppositories 
Standart therapy + 
«Longidaza» 
injections 
Excellent on the level of the standard 
rate of pharmacotherapy 94,2 
Normilized 16,6 28,6 35,4 
Corrected 25,6 36,4 35,2 
Unaltered 52,0 29,2 23,6 
Excellent level of standards after 
additional pharmacological correction 
77,6 65,6 58,8 
 
In determining its own corrective effects of 
treatment, regimens compared with standard 
conservative therapy found that the practically all 
indicators of immune status of all these diagram 
effectiveness standard, as the average degree of 
correction in almost all performance parameters are 
proved positive. 
 
Figure 2. Condition of the metabolic status of erythrocytes in patients with chronic adnexitis in the exacerbation phase on a 
background of therapies
The maximum number of points set for the 
diagram, including «Longidaza» in the form of 
injections - 1097 points. Positive dynamics of 
Immune status coincided with the clinical effect of 
different treatments. 
For example, 36.8% of patients after standard 
treatment with chronic adnexitis in the exacerbation 
phase has pain, 15% - dysmenorrhea, 36.8 - increase 
the basal rate during menstruation, at 32.2% there is 
an increase of leukocytes in the smears (Table. 10). 
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Table 10. 
Clinical effectiveness of different treatment regimens of patients with chronic adnexitis in the exacerbation phase 






























































































































1. Standard treatment (ST)  32,2 32,2 36,8 36,8 15,0 40,0 




































The maximum decrease in clinical 
manifestations observed after the application of an 
additional «Longidaza» in the form of injections, 
after the appointment of the drug were no relapses of 
diseases in 13.3% of patients  was observed and 
dysmenorrhea, increase in white blood cells in the 
smears and increase basal temperature. 
With multiple correlation matrix the Spearman 
between exponent of immune, metabolic status and 
clinical manifestations were significant, both positive 
and negative connections, testified of the 
interdependence of laboratory and clinical long-
exponent. 
A number of indicators have the greatest number 
of these relation: concentration in the blood plasma 
FNOα, C3 component сomplement system, α1-
antitrypsin, and cervical-vaginal lavage - the 
concentration of IL-18, the activity of superoxide 
dismutase. 
In patients with chronic adnexitis in the 
exacerbation phase has been a violation of a number 
of indicators of immune status, as in system, and at 
the local level, at the same time it is carried out the 
standard pharmacological correction in these patients 
does not allow fully resolve as the immune, so and 
metabolic status, which dictates the desirability of 
research and testing in clinical trials of more 
pharmacological agents and methods 
immunorehabilitation patients with chronic adnexitis 
in the exacerbation phase, in this connection, we have 
established Immune efficacy of «Gepon» and 
«Longidaza» in patients with chronic chronic 
adnexitis in the exacerbation phase. In the end, we 
used the drug «Gepon» and «Longidaza» in two 
dosage forms - suppositories and injectable form. 
Use in addition to standard pharmacotherapy 
chronic adnexitis in the exacerbation phase «Gepon» 
helped normalize blood levels only α1-antitrypsin, 
while the use of «Longidaza» in the form of 
suppositories further normalizes the concentration of 
CRP, INFα and C3 component of the complement 
system. This is the use of an additional «Longidaza» 
injection enabled normalized larger number of 
indicators at the system level. 
The use of «Gepon» does not have a 
normalizing effect on the changed ndicators were in 
vaginal-cervical lavage women with chronic 
adnexitis in the exacerbation phase, whereas the use 
of «Longidaza» as suppositories normalizes studied 
indices of metabolic status, whereas injectable 
normalizes a level of α2-macroglobulin and INFα. 
The use of «Gepon» corrects inside the 
erythrocytes malonic dial level and sorption capacity 
of erythrocyte, «Longidaza» in the form of 
suppositories - further sorptive capacity glycocalyx, 
while the use of «Longidaza» in the form of 
injections normalize sorption properties of 
erythrocytes. 
Thus, on the basis of the research we can 
recommend to use in practical public health sketch 
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pharmacologists immuno-metabolic rehabilitation in 
patients with chronic adnexitis in the exacerbation 
phase using «Longidaza» in the form of injections. 
Less effective, it corrects the disturbed immune 
parameters and oxidative status of the treatment 
regimen with the use of this drug in the form of 
suppositories. 
RECOMMENDATION 
Taking into account the results expressed in the 
form of the article, we can, but to formulate the 
recommendations and prospects of further 
development of the theme: 
– In order to mitigate immune and oxidant 
disturbances in patients with chronic adnexitis in the 
exacerbation phase in the form of injection (3000 IU 
intramuscularly 1 time per day for 5 days) is possible 
the use of exacerbation «Longidaza». 
– To obtain objective facts on the severity of 
Immune disorders in patients with chronic adnexitis 
in the exacerbation phase usefully be measured in the 
blood plasma concentration FNOα, C3-component 
system someone plementa, α1-antitrypsin, and 
cervical-vaginal lavage - the concentration of IL-18, 
the activity of superoxide dismutase. 
– Use in the educational process of medical 
universities the knowledge about the reacting 
immunocorrective and antioxidant effects 
«Longidaza» and «Gepon» in terms of exacerbation 
of chronic adnexitis. 
CONCLUSIONS 
After the standard treatment in patients with 
chronic adnexitis in the exacerbation phase has not 
reached the level of healthy donor concentration in 
plasma IL-18, C3, C4 components of the complement 
system, α1-antitrypsin, α2-macroglobulin, C-reactive 
protein in vaginal-cervical lavage concentrations of 
stable metabolites of nitric oxide, IL-10 and α1-
antitrypsin, α2-macroglobulin and endoglobular 
concentrations of malonic dial. 
Use in addition to standard pharmacotherapy of 
chronic adnexitis «Gepon» (in a dosage of 10 mg per 
1 times a day for 5 days) helped further to normalize 
at B level α1-antitrypsin, inside red blood cells to 
correct the level of malonic dial and total sorption 
capacity blood cells without significant effects on 
performance at the local level. 
Appointment of patients with chronic adnexitis 
in the exacerbation phase, in addition to the standard 
treatment regimen, «Longidaza» in the form of 
suppositories (in a dosage of 1 suppository 3000 per 
recti 1 times a day for 5 days) complement 
normalizes blood plasma concentration of C-reactive 
protein, INFα and C3 component of the complement 
system, sorption capacity glicocalyx red blood cells, 
and vaginal-cervical lavage almost all the studied 
indicators of metabolic status. 
Using an additional «Longidaza» injection (in a 
dosage of 1 suppository 3000 intramuscularly 1 time 
per day for 5 days) in patients with chronic adnexitis 
in the exacerbation phase helped normalize the 
greater number of indicators at the system level: 
sorption properties of red blood cells, and at the local 
level only level α2-macroglobulin and INFα. 
Using «Gepon» normalizes 16.6% of the 
indicators (2.8 times more effective than standard 
therapy), and the use of «Lonegidaza» in the form of 
suppositories - 28.6% (4.9 times more effective than 
standard therapy), which reduced the number of 
indicators other than the level of the norm to 77.6 and 
65.6%. At the same time the using of «Longidaza» in 
the form of  injections in patients with chronic 
adnexitis in the exacerbation phase allowed 
normalized larger number of indicators, making 
lower the number of modify to 58.8% (6.1 times 
more effective than standard therapy). 
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